ADXN

Addex Reports Full Year 2025 Financial Results and Provides Corporate Update

Addex Therapeutics makes strategic advancements in neurological drug development

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>&lt;link type=&quot;text/css&quot; rel=&quot;stylesheet&quot; href=&quot;https://www.globenewswire.com/styles/gnw_nitf.css&quot;&gt;&lt;/li...</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Addex Therapeutics reported significant advances in its drug pipeline, particularly the GABAB PAM for chronic cough and dipraglurant for brain injury recovery. These developments, alongside the regaining of rights to ADX71149, may enhance investor sentiment and valuation in the near term.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Addex&#039;s GABAB PAM chronic cough candidate shows positive preclinical results.</li><li>Dipraglurant repositioned for brain injury recovery with new collaboration.</li><li>ADX71149 asset rights regained, enhancing pipeline for further development.</li><li>Indivior advances GABAB PAM candidate through regulatory studies.</li><li>Cash position of CHF 1.6 million as of December 31, 2025.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Indivior (INDV)</strong>: Advancing collaboration with Addex on GABAB PAM drug, benefiting both parties.</li><li><strong>Sinntaxis (n/a)</strong>: New collaboration for exclusive licensing regarding brain injury recovery.</li><li><strong>Neurosterix (n/a)</strong>: Addex holds a 20% equity interest, enhancing its asset portfolio.</li><li><strong>Stalicla SA (n/a)</strong>: Strategic investment confirms Addex&#039;s commitment to innovative neurological treatments.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This news falls under &#039;Corporate Developments&#039; as it highlights strategic moves in drug development and collaborations, which could directly influence ADXN&#039;s market position and future revenue potential.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Positive preclinical results could lead to increased interest and investment.</li><li>Revenues could improve with successful IND studies and collaborations.</li><li>Regained rights to ADX71149 opens doors for potential partnerships.</li><li>Strategic investments may attract institutional interest in Addex.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Addex reported a total net loss of CHF 6.7 million in 2025.</li><li>GABAB PAM chronic cough candidate advanced due to strong preclinical data.</li><li>Cash position was CHF 1.6 million at December 31, 2025.</li><li>Regaining rights to ADX71149 enhances development options in the pipeline.</li><li>Indivior&#039;s collaboration has progressed, validating Addex&#039;s development strategy.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Invest in ADXN for potential upside driven by recent pipeline developments in 2026.</p>
  </section>
</section>


<article>
    <header>
        <h1>Addex Reports Full Year 2025 Financial Results and Provides Corporate Update</h1>
        <p><strong>Geneva, Switzerland, April 30, 2026</strong> - <a href="https://www.globenewswire.com/Tracker?data=LQuqYO3pkB88ljUi32uIAvWAnjsQDEjg8M7g2XLh0Uoz0ebJogGS7lE90m-UKomT-bmkigC0Sa-ok6uhsrI_F9XYA3WuQBsoSeiOaqhEemYMHQR9hp8nejoaVZCASwX8" rel="nofollow" target="_blank">Addex Therapeutics</a> (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company, announced its full-year financial results for 2025 and provided an update on its corporate developments.</p>
    </header>

    <section>
        <h2>Significant Progress in Drug Development</h2>
        <p>During 2025, Addex Therapeutics achieved notable advancements in its drug development initiatives. The company focused on its GABAB PAM program aimed at treating chronic cough, reporting positive outcomes from various preclinical disease models. CEO Tim Dyer stated, "We have delivered robust and sustained progress throughout 2025, successfully meeting our key objectives across both drug development and strategic business initiatives."</p>
        <p>Moreover, the company regained rights to its mGlu2 PAM asset, <strong>ADX71149</strong>, alongside its dipraglurant asset, which positions Addex with two Phase 2 clinical candidates primed for further development.</p>
    </section>

    <section>
        <h2>Strategic Business Developments</h2>
        <p>In conjunction with advancing its clinical assets, Addex entered an option and collaboration agreement with Sinntaxis, providing exclusive licensing for intellectual property related to mGlu5 NAM in brain injury recovery. This strategic move is designed to bolster the clinical potential of dipraglurant.</p>
        <p>Additionally, under its partnership with Indivior, the GABAB PAM candidate has moved through IND-enabling studies, showcasing the viability of the allosteric modulator approach for substance use disorders. Addex has also reaffirmed its commitment to innovation by investing in Stalicla SA, enhancing its portfolio of treatments for neurological conditions.</p>
    </section>

    <section>
        <h2>2025 Financial Performance Overview</h2>
        <p>The financial results for FY 2025 revealed key insights into the company's economic health:</p>
        <table>
            <thead>
                <tr>
                    <th>CHF' thousands</th>
                    <th>2025</th>
                    <th>2024</th>
                    <th>Change</th>
                </tr>
            </thead>
            <tbody>
                <tr>
                    <td>Income</td>
                    <td>173</td>
                    <td>410</td>
                    <td>(237)</td>
                </tr>
                <tr>
                    <td>R&D expenses</td>
                    <td>(672)</td>
                    <td>(854)</td>
                    <td>182</td>
                </tr>
                <tr>
                    <td>G&A expenses</td>
                    <td>(2,316)</td>
                    <td>(2,311)</td>
                    <td>(5)</td>
                </tr>
                <tr>
                    <td><strong>Total operating loss</strong></td>
                    <td><strong>(2,815)</strong></td>
                    <td><strong>(2,755)</strong></td>
                    <td><strong>(60)</strong></td>
                </tr>
                <tr>
                    <td>Net loss from continuing operations</td>
                    <td>(6,843)</td>
                    <td>(4,909)</td>
                    <td>(1,934)</td>
                </tr>
                <tr>
                    <td>Net profit/(loss) for the period</td>
                    <td>(6,729)</td>
                    <td>7,056</td>
                    <td>(13,785)</td>
                </tr>
            </tbody>
        </table>
        <p>As of December 31, 2025, Addex reported a cash position of <strong>CHF 1.6 million</strong>, demonstrating the company's commitment to navigating the challenges of research and development in the biopharmaceutical sector.</p>
    </section>
    
    <footer>
        <p>This release marks a significant moment for Addex (ADXN) as it builds upon strategic initiatives and focuses on advancing therapies targeting neurological disorders.</p>
    </footer>
</article>

Addex Therapeutics reported significant advances in its drug pipeline, particularly the GABAB PAM for chronic cough and dipraglurant for brain injury recovery. These developments, alongside the regaining of rights to ADX71149, may enhance investor sentiment and valuation in the near term.

Addex Reports Full Year 2025 Financial Results and Provides Corporate Update

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News